Olopatadine
PATANOL
Pronunciation: oe-loe-pa-TA-deen
“Hollow Pat-a-day”
What it isTopical H1 antagonist with mast-cell stabilization; allergic conjunctivitis and rhinitis.
Why this oneAvailability as both eye drops and nasal spray distinguishes it from most dual-action topical antihistamines.
What limits itLocal irritation and bitter taste intranasally are the main drawbacks; systemic effects are minimal.
FDA-approved for
- allergic conjunctivitis (1996)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Ocular itch due to allergic conjunctivitis (OTC) | Adults & children ≥2 yr | 1 drop in affected eye(s) QD | 1 drop QD | 1 drop per eye per day |
Renal Undefined
Hepatic Undefined
Instructions
- For ophthalmic use only
- Do not use more than 1 drop per eye per day
- If using other eye drops, wait at least 5 minutes between products
- Replace cap after each use
- Children under 2 years: consult a doctor
Available strengths
- drops 0.1, 0.2, 0.7 %
- sol 1, 2, 7 mg/mL
- nasal spray 665 mcg/spray
Pregnancy Undefined
Lactation Undefined
Cost
Olopatadine (PATANOL)
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.1 % | drops | per unit | not offered | |
| 0.2 % | drops | per unit | not offered | |
| 0.7 % | drops | per unit | not offered |
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Olopatadine is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Generic entry2014
NO BOXED WARNINGS
Principal riskLocal irritation; bitter taste intranasally
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.